Ocugen up 11% premarket on FY results

Ocugen (OCGN) FY results: Revenues: $0; Net loss: ($20.2M) (-11.0%); loss/share: ($1.46) (+60.2%); Quick Assets: $7.4M.

As of March 20, the company has completed over 95% in Phase 3 oGVHD study (OCU300); topline results anticipated by year-end 2020.

Yesterday, Ocugen drew down an additional $0.5M under its loan agreement with EB5 Life Sciences, L.P.

Shares are up11%premarket.

Previously: Ocugen reports FY results (March 27)

See all stocks on the move »